Related references
Note: Only part of the references are listed.Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients
Jingjing Zhang et al.
JOURNAL OF NUCLEAR MEDICINE (2019)
Unmet Needs in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms (WHO G3)
Halfdan Sorbye et al.
NEUROENDOCRINOLOGY (2019)
Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study
Esben Andreas Carlsen et al.
ENDOCRINE-RELATED CANCER (2019)
Pembrolizumab treatment of advanced neuroendocrine tumors: Results from the phase II KEYNOTE-158 study.
Jonathan R. Strosberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Temozolomide in grade III neuroendocrine neoplasms (G3 NENs): A multicenter retrospective review.
David Chan et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
CAPTEM in Metastatic Well-Differentiated Intermediate to High Grade Neuroendocrine Tumors: A Single Centre Experience
Arvind Sahu et al.
JOURNAL OF ONCOLOGY (2019)
Capecitabine and temozolomide combination for treatment of high-grade, well-differentiated neuroendocrine tumour and poorly-differentiated neuroendocrine carcinoma - retrospective analysis
Wojciech Rogowski et al.
ENDOKRYNOLOGIA POLSKA (2019)
A Phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) S1609: The neuroendocrine cohort
Sandip Pravin Patel et al.
CANCER RESEARCH (2019)
Peptide receptor radionuclide therapy (PRRT) in European Neuroendocrine Tumour Society (ENETS) grade 3 (G3) neuroendocrine neoplasia (NEN) - a single-institution retrospective analysis
Sue Ping Thang et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2018)
Well-differentiated pancreatic neuroendocrine tumours (PanNETs) and poorly differentiated pancreatic neuroendocrine carcinomas (PanNECs): concepts, issues and a practical diagnostic approach to high-grade (G3) cases
Aatur D. Singhi et al.
HISTOPATHOLOGY (2018)
The Problem of High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms Well-Differentiated Neuroendocrine Tumors, Neuroendocrine Carcinomas, and Beyond
Halfdan Sorbye et al.
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA (2018)
Investigation of receptor radionuclide therapy with Lu-177-DOTATATE in patients with GEP-NEN and a high Ki-67 proliferation index
Silvia Nicolini et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2018)
Sunitinib shrinks NET-G3 pancreatic neuroendocrine neoplasms
Yuki Mizuno et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2018)
Clinical and Biomarker Evaluations of Sunitinib in Patients with Grade 3 Digestive Neuroendocrine Neoplasms
Anna Pellat et al.
NEUROENDOCRINOLOGY (2018)
Clinical relevance of different WHO grade 3 pancreatic neuroendocrine neoplasms based on morphology
Xu Han et al.
ENDOCRINE CONNECTIONS (2018)
Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma A Preplanned Interim Analysis of a Clinical Trial
Sandra P. D'Angelo et al.
JAMA ONCOLOGY (2018)
Pembrolizumab (P) monotherapy in patients with previously treated metastatic high grade neuroendocrine neoplasms (HG-NENs).
Namrata Vijayvergia et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: A trial of the ECOG-ACRIN Cancer Research Group (E2211).
Pamela L. Kunz et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
L. Horn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
1317PTreatment outcomes for well differentiated grade 3 neuroendocrine tumors (NET G3)
L Apostolidis et al.
ANNALS OF ONCOLOGY (2018)
1308OActivity & safety of spartalizumab (PDR001) in patients (pts) with advanced neuroendocrine tumors (NET) of pancreatic (Pan), gastrointestinal (GI), or thoracic (T) origin, & gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who have progressed on prior treatment (Tx)
J C Yao et al.
ANNALS OF ONCOLOGY (2018)
Comparative Study of Lung and Extrapulmonary Poorly Differentiated Neuroendocrine Carcinomas: A SEER Database Analysis of 162,983 Cases
Arvind Dasari et al.
CANCER (2018)
Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study
S. Faivre et al.
ANNALS OF ONCOLOGY (2017)
The Clinicopathologic Heterogeneity of Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: Morphological Differentiation and Proliferation Identify Different Prognostic Categories
Massimo Milione et al.
NEUROENDOCRINOLOGY (2017)
Somatostatin receptor expression related to TP53 and RB1 alterations in pancreatic and extrapancreatic neuroendocrine neoplasms with a Ki67-index above 20%
Bjoern Konukiewitz et al.
MODERN PATHOLOGY (2017)
Whole-genome landscape of pancreatic neuroendocrine tumours
Aldo Scarpa et al.
NATURE (2017)
Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors
J. Strosberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Treatment Response and Outcomes of Grade 3 Pancreatic Neuroendocrine Neoplasms Based on Morphology Well Differentiated Versus Poorly Differentiated
Nitya Raj et al.
PANCREAS (2017)
Everolimus in Pancreatic Neuroendocrine Carcinomas G3
Francesco Panzuto et al.
PANCREAS (2017)
Results after surgical treatment of liver metastases in patients with high-grade gastroenteropancreatic neuroendocrine carcinomas
R. B. Galleberg et al.
EJSO (2017)
Rb Loss and KRAS Mutation Are Predictors of the Response to Platinum-Based Chemotherapy in Pancreatic Neuroendocrine Neoplasm with Grade 3: A Japanese Multicenter Pancreatic NEN-G3 Study
Susumu Hijioka et al.
CLINICAL CANCER RESEARCH (2017)
Well-Differentiated Neuroendocrine Tumors with a Morphologically Apparent High-Grade Component: A Pathway Distinct from Poorly Differentiated Neuroendocrine Carcinomas
Laura H. Tang et al.
CLINICAL CANCER RESEARCH (2016)
A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas
Laura H. Tang et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2016)
Recent Updates on Neuroendocrine Tumors From the Gastrointestinal and Pancreatobiliary Tracts
Joo Young Kim et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2016)
Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study
James C. Yao et al.
LANCET (2016)
PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma
Paul T. Nghiem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Gastroenteropancreatic Well-Differentiated Grade 3 Neuroendocrine Tumors: Review and Position Statement
Romain Coriat et al.
ONCOLOGIST (2016)
Long-term outcomes and prognostic factors in neuroendocrine carcinomas of the pancreas: Morphology matters
Stefano Crippa et al.
SURGERY (2016)
Genomic profiling to distinguish poorly differentiated neuroendocrine carcinomas arising in different sites
Emily K. Bergsland et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
The High-grade (WHO G3) Pancreatic Neuroendocrine Tumor Category Is Morphologically and Biologically Heterogenous and Includes Both Well Differentiated and Poorly Differentiated Neoplasms
Olca Basturk et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2015)
Post-first-line FOLFOX chemotherapy for grade 3 neuroendocrine carcinoma
J. Hadoux et al.
ENDOCRINE-RELATED CANCER (2015)
Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms
M. Heetfeld et al.
ENDOCRINE-RELATED CANCER (2015)
Surgical Resection Improves the Outcome of the Patients With Neuroendocrine Tumor Liver Metastases Large Data From Asia
Shunda Du et al.
MEDICINE (2015)
Expression Analysis of Genes Involved in DNA Repair or Synthesis in Mixed Neuroendocrine/Nonneuroendocrine Carcinomas
Marco Volante et al.
NEUROENDOCRINOLOGY (2015)
Microsatellite unstable gastrointestinal neuroendocrine carcinomas: a new clinicopathologic entity
Nora Sahnane et al.
ENDOCRINE-RELATED CANCER (2015)
Neuroendocrine tumor G3: a pancreatic well-differentiated neuroendocrine tumor with a high proliferative rate
Hiroki Tanaka et al.
CLINICAL JOURNAL OF GASTROENTEROLOGY (2015)
Gastroenteropancreatic High-Grade Neuroendocrine Carcinoma
Halfdan Sorbye et al.
CANCER (2014)
Management of a metastasized high grade insulinoma (G3) with refractory hypoglycemia: Case report and review of the literature
Michael Scharf et al.
PANCREATOLOGY (2014)
Pancreatic neuroendocrine tumors: Pathologic and molecular characteristics
Chanjuan Shi et al.
SEMINARS IN DIAGNOSTIC PATHOLOGY (2014)
Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study
H. Sorbye et al.
ANNALS OF ONCOLOGY (2013)
Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience
Robert L. Fine et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Are G3 ENETS neuroendocrine neoplasms heterogeneous?
Fritz-Line Velayoudom-Cephise et al.
ENDOCRINE-RELATED CANCER (2013)
Diagnostic utility of MS-MLPA in DNA methylation profiling of adenocarcinomas and neuroendocrine carcinomas of the colon-rectum
Daniela Furlan et al.
VIRCHOWS ARCHIV (2013)
Prolonged Clinical Benefit of Everolimus Therapy in the Management of High-Grade Pancreatic Neuroendocrine Carcinoma
Paula J. Fonseca et al.
CASE REPORTS IN ONCOLOGY (2013)
Colorectal Poorly Differentiated Neuroendocrine Carcinomas and Mixed Adenoneuroendocrine Carcinomas: Insights Into the Diagnostic Immunophenotype, Assessment of Methylation Profile, and Search for Prognostic Markers
Stefano La Rosa et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2012)
Small Cell and Large Cell Neuroendocrine Carcinomas of the Pancreas are Genetically Similar and Distinct From Well-differentiated Pancreatic Neuroendocrine Tumors
Shinichi Yachida et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2012)
First-Line Chemotherapy With Capecitabine and Temozolomide in Patients With Metastatic Pancreatic Endocrine Carcinomas
Jonathan R. Strosberg et al.
CANCER (2011)
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors.
Eric Raymond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Everolimus for Advanced Pancreatic Neuroendocrine Tumors.
James C. Yao et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
DAXX/ATRX, MEN1, and mTOR Pathway Genes Are Frequently Altered in Pancreatic Neuroendocrine Tumors
Yuchen Jiao et al.
SCIENCE (2011)
Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: Results of a phase II study
James C. Yao et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
One hundred years after Carcinoid: Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States
James C. Yao et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Pulmonary and extrapulmonary poorly differentiated large cell neuroendocrine carcinomas - Diagnostic and prognostic features
Antongiulio Faggiano et al.
CANCER (2007)
Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors
MH Kulke et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Share Paper
